Evidence map›Paper›PMID 38572315›Full record

ArticleFrontiers in cellular and infection microbiology2024

Clinical distribution of carbapenem genotypes and resistance to ceftazidime-avibactam in Enterobacteriaceae bacteria.

Xueyun Zhu, Caixia Guo, Shengxi Xu, Fei Lv, Zhusheng Guo, Sisi Lin, CongZhu Yang, Zhuliang Deng, Shaofeng Chen, Ya Huang and 2 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in cellular and infection microbiology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.5field-weighted citation impact, top 44% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Phylogenetic analysis ofIranian journal of microbiology · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 1 country.

Xueyun ZhuGuangdong Provincial Key Laboratory of Medical Molecular Diagnostics, School of Medical Technology, The First Dongguan Affiliated Hospital, Guangdong Medical University, Dongguan, China.
Caixia GuoThe Fourth Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.
Shengxi XuGuangdong Provincial Key Laboratory of Medical Molecular Diagnostics, School of Medical Technology, The First Dongguan Affiliated Hospital, Guangdong Medical University, Dongguan, China.
Fei LvDepartment of Laboratory Medicine, Dongguan Songshan Lake Tungwah Hospital, Dongguan, China.
Zhusheng GuoDepartment of Laboratory Medicine, Dongguan Songshan Lake Tungwah Hospital, Dongguan, China.
Sisi LinDepartment of Laboratory Medicine, Dongguan Songshan Lake Tungwah Hospital, Dongguan, China.
CongZhu YangDepartment of Laboratory Medicine, Dongguan Songshan Lake Tungwah Hospital, Dongguan, China.
Zhuliang DengDepartment of Laboratory Medicine, Dongguan Songshan Lake Tungwah Hospital, Dongguan, China.
Shaofeng ChenDepartment of Laboratory Medicine, Dongguan Songshan Lake Tungwah Hospital, Dongguan, China.
Ya HuangDepartment of Laboratory Medicine, Dongguan Songshan Lake Tungwah Hospital, Dongguan, China.
Zuguo ZhaoGuangdong Provincial Key Laboratory of Medical Molecular Diagnostics, School of Medical Technology, The First Dongguan Affiliated Hospital, Guangdong Medical University, Dongguan, China.
Lu LiGuangdong Provincial Key Laboratory of Medical Molecular Diagnostics, School of Medical Technology, The First Dongguan Affiliated Hospital, Guangdong Medical University, Dongguan, China.
Guangdong Medical College · CNTung Wah Hospital · CNSongshan Lake Materials Laboratory · CNGuangzhou Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Bacterial resistance is a major threat to public health worldwide. To gain an understanding of the clinical infection distribution, drug resistance information, and genotype of CRE in Dongguan, China, as well as the resistance of relevant genotypes to CAZ-AVI, this research aims to improve drug resistance monitoring information in Dongguan and provide a reliable basis for the clinical control and treatment of CRE infection. Methods: VITEK-2 Compact automatic analyzer was utilized to identify 516 strains of CRE collected from January 2017 to June 2023. To determine drug sensitivity, the K-B method, E-test, and MIC methods were used. From June 2022 to June 2023, 80 CRE strains were selected, and GeneXpert Carba-R was used to detect and identify the genotype of the carbapenemase present in the collected CRE strains. An in-depth analysis was conducted on the CAZ-AVI Results: This study identified 516 CRE strains, with the majority (70.16%) being Conclusions: The CRE strains isolated from Dongguan region demonstrated a high resistance rate to various antibiotics used in clinical practice but a low resistance rate to tigecycline. These strains produce Class A serine carbapenemases and Class B metals β-lactamases, with the majority of them carrying

Indexed as

Azabicyclo CompoundsCarbapenemsCeftazidimeEnterobacteriaceaeAnti-Bacterial AgentsBacterial Proteinsbeta-LactamasesCephalosporinsDrug CombinationsGenotypeHospital Distribution SystemsKlebsiella pneumoniaeMicrobial Sensitivity TestsTigecyclineAnti-Bacterial Agentsavibactam, ceftazidime drug combinationAzabicyclo CompoundsBacterial Proteinsbeta-LactamasesCarbapenemsCeftazidimeCephalosporinsDrug CombinationsTigecyclineblaKPCBlaNDMCarbapenem-resistant Enterobacteriaceaeceftazidime-avibactamGeneXpert Carba-R

Identifiers

PMID38572315
PMCPMC10987847
OpenAlexW4393012182

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.